Game-Changing Cell Line Development Platforms: How Flexible Strategies, Integrated Technologies, & Expert Workflows are Driving Clinical Success

Your biologic is only as strong as the cell line that it’s built on and the partner with whom you choose to develop it. However, selecting the right cell line platform can be a complex, time-consuming, and multifaceted process. Getting this wrong runs the risk of low titers, unstable expression, or scale-up failures, which can incur additional costs and delayed timelines.

Access our on-demand webinar to hear from a live panel of cell line development experts from Abzena, Revvity, and ProteoNic Biosciences, as they explore how flexible, next-generation cell line platforms, like AbZelectPRO™, deliver higher productivity, rapid timelines, and regulatory confidence- offering developers a de-risked and streamlined path to the clinic. From integrated analytics to product quality and process efficiency, our knowledgeable panel will share insights on how to tackle the biggest challenges that you may be facing in CLD today, so that you can focus on getting to your next target inflection point faster.

What You’ll Learn:

• • Learn how Abzena’s enhanced mammalian CLD platforms, AbZelectPRO™ , AbZelectPRO™-KO , and AbZelectPRO™ -KO+ – enable the rapid progression from DNA to RCB in 10 weeks for therapeutic antibodies & difficult-to-express proteins
  • Discover how Revvity’s CHOSOURCE™ GS Knockout expression systems are combined with Abzena’s de-risked CLD workflows and ProteoNic’s next-gen 2G UNic® vector technology to offer enhanced productivity and high-quality titers up to 10g/L
  • Explore how our extensive in-house analytical portfolio ensures an efficient, stable, & scalable production – simplifying the IND and delivering customers’ complex biologics successfully to the clinic

Download Webinar

Speakers

Brett Verstak, PhD – Head of Cell Line Development, Abzena
Brett has over 11 years’ experience in the biopharmaceutical sector, where he has amassed a wealth of managerial and scientific expertise. His extensive background as a cellular biologist and protein biochemist is complemented by his specialised knowledge in upstream and downstream bioprocessing, stable cell line development, and the manufacturing of biologics, including antibodies, fragments, fusion proteins, and vaccines. Brett’s profound understanding of these areas has made him an invaluable asset in the field. His significant experience as a technical project manager further underscores his capabilities, as he has successfully led project governance for multiple programs within Abzena’s global portfolio. Brett’s leadership ensures the seamless delivery of projects to stakeholders, consistently meeting and exceeding expectations.

Maurice van der Heijden, PhD – Senior Director R&D, ProteoNic Biosciences
Maurice van der Heijden has extensive expertise in molecular and cell biology studies. After obtaining a PhD in molecular virology from Leiden University, he held postdoctoral positions at Leiden and Utrecht Universities. He brings his experience in antibody discovery from Janssen Pharmaceutical Companies to his position at ProteoNic where he oversees the scientific development program and technical customer support.

Delphine Cougot, PhD – Head of Bioprocess R&D, Revvity
Delphine is leading the Bioproduction R&D team at Revvity and has 16 years of R&D experience in academic and industry settings. Delphine holds a PhD in Oncogenesis from the University of Paris. Following a postdoctoral position at the Gurdon Institute/University of Cambridge, she joined Horizon to lead the standardisation of immunohistochemistry assays across testing laboratories. Now in the Bioproduction group, she leads the R&D programmes which apply gene editing technologies to the improvement of bioproduction products and services.